يعرض 1 - 8 نتائج من 8 نتيجة بحث عن '"Jiménez Flores, José Antonio"', وقت الاستعلام: 0.76s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Martini G, Belli V, Napolitano S, Ciaramella V, Ciardiello D Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples. Belli A Hepatobiliary Surgical Oncology Unit, Istituto Nazionale Tumori—Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli. Puig I, Ramirez L, Chicote I, Garcia Palmer H Translational Program, Stem Cells and Cancer Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Mancuso F, Caratu G, Vivancos A Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Serres X Radiodiagnòstic (IDI), Vall d’Hebron Hospital Universitari, Barcelona, Spain. Fasani R, Jimenez J Molecular Oncology Lab, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Ros J, Baraibar I, Elez E, Tabernero J Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Dienstmann R Oncology Data Science, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Argilés G Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Memorial Sloan Kettering Cancer Center, New York, USA, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: ESMO Open;8(3); https://doi.org/10.1016/j.esmoop.2023.101198Test; Martini G, Belli V, Napolitano S, Ciaramella V, Ciardiello D, Belli A, et al. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer. ESMO Open. 2023 Jun;8(3):101198.; https://hdl.handle.net/11351/9478Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Gunda A, Basavaraj C, Serkad V CP, Adinarayan M, Kolli R, Siraganahalli Eshwaraiah M OncoStem Diagnostics, Bengaluru, Karnataka, India. Saura C, Ruiz F, Gomez P, Peg V, Jimenez J Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: The Breast;63; https://doi.org/10.1016/j.breast.2022.02.010Test; Gunda A, Basavaraj C, Serkad V CP, Adinarayan M, Kolli R, Siraganahalli Eshwaraiah M, et al. A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort. The Breast. 2022 Jun;63:1–8.; https://hdl.handle.net/11351/7897Test; 000788392200001

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Frigola J, Carbonell C, Soleda M, Amat R Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Irazno P, Pardo N, Callejo A, Cedres S, Martinez-Marti A, Navarro A Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Jimenez J Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Hernandez-Losa J Servei de Patologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vivancos A Cancer Genomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Felip E Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Journal for ImmunoTherapy of Cancer;10(4); http://dx.doi.org/10.1136/jitc-2021-004197Test; Frigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, et al. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. J Immunother Cancer. 2022 Apr;10(4):e004197.; https://hdl.handle.net/11351/8030Test; 000788620500001

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Frigola J, Carbonell C, Amat R Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Navarro A, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Jimenez J, Nuciforo P Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Sansano I Unitat de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Mancuso FM, Vivancos A Cancer Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Felip E Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Molecular Oncology;15(4); https://doi.org/10.1002/1878-0261.12891Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00938; Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, et al. Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer. Mol Oncol. 2021 Apr;15(4):887–900.; https://hdl.handle.net/11351/6634Test; 000605076800001

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Serna G, Alonso L, Fasani R, Jimenez J, Nuciforo P Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Ruiz-Pace F, Comas R, Dienstmann R Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Hernando J, Elez E, Capdevila J Servei d’Oncologia Mèdica, Unitat de Tumors gastrointestinals i endocrins, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. Landolfi S Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Tabernero J Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf; image/jpeg

    العلاقة: Annals of Oncology;31(10); https://doi.org/10.1016/j.annonc.2020.06.003Test; Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 Oct;31(10):1366–75.; https://hdl.handle.net/11351/6378Test; 000574680100001

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Dienstmann R, Aguilar S, Viaplana C, Ruiz-Pace F Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Garralda E, Sala G, Oaknin A, Saura C, Oliveira M, Balmaña J, Carles J, Macarulla T, Elez E, Alsina M, Braña I, Felip E, Tabernero J Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. González-Zorelle J Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Cancer Genomics Lab, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Grazia LoGiacco D, Ogbah Z, Ramos Masdeu L, Mancuso F, Vivancos A Cancer Genomics Lab, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Fasani R, Jimenez J, Martinez P, Nuciforo P Molecular Oncology Lab, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Rodon J Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: JCO Precision Oncology;4; https://doi.org/10.1200/PO.19.00398Test; Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F, et al. Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. JCO Precis Oncol. 2020 May 14;4:505–13.; https://hdl.handle.net/11351/6495Test; 000538154100001

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Serna G, Simonetti S, Fasani R, Guardia X, Gallego P, Jimenez J, Nuciforo P Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Pagliuca F University of Naples Federico II, Department of Advanced Biomedical Sciences, Pathology Section, Naples, Italy. Peg V, Ramon Y Cajal S Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Saura C Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Breast;53; https://doi.org/10.1016/j.breast.2020.07.002Test; Serna G, Simonetti S, Fasani R, Pagliuca F, Guardia X, Gallego P, et al. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. Breast. 2020 Oct 1;53:102–10.; https://hdl.handle.net/11351/6403Test; 000573862600016

  8. 8
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Moserle L, Pons R, Martínez-Lozano M, Jiménez-Valerio GA Tumor Angiogenesis Group, ProCURE Program, Catalan Institute of Oncology, OncoBell Program, IDIBELL, Barcelona, Spain. Vidal A Tumor Angiogenesis Group, ProCURE Program, Catalan Institute of Oncology, OncoBell Program, IDIBELL, Barcelona, Spain. Suárez C, Jiménez J, Carles J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Trilla E Servei de Cirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Torres I Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: EMBO Molecular Medicine;12; https://doi.org/10.15252/emmm.201911889Test; info:eu-repo/grantAgreement/EC/FP7/281830; info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2016-79347-R; info:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-107557RB-I00; info:eu-repo/grantAgreement/ES/PE2013-2016/DTS17%2F00194; info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR771; Moserle L, Pons R, Martínez‐Lozano M, Jiménez‐Valerio GA, Vidal A, Suárez C, et al. Kidney cancer PDOXs reveal patient‐specific pro‐malignant effects of antiangiogenics and its molecular traits. EMBO Mol Med. 2020 Dec 7;12:e11889.; https://hdl.handle.net/11351/6279Test; 000586314700001